Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Domatinostat - 4SC

Drug Profile

Domatinostat - 4SC

Alternative Names: 4SC-202

Latest Information Update: 22 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nycomed
  • Developer 4SC
  • Class Antineoplastics; Benzamides; Pyrazoles; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action BRD4 protein modulators; HDAC1 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastrointestinal cancer
  • Phase I/II Malignant melanoma
  • Preclinical Pancreatic cancer; Small cell lung cancer
  • No development reported Cancer; Haematological malignancies

Most Recent Events

  • 01 Nov 2019 4SC and The Netherlands Cancer Institute plan the pivotal phase Ib/II DONIMI trial in Malignant melanoma (Combination therapy, Neoadjuvant therapy, Late-stage disease) in Netherlands (PO), in December 2019 , (NCT04133948)
  • 17 Oct 2019 4SC AG plans the pivotal phase II MERKLIN 2 trial for Merkel cell carcinoma (Combination therapy, Second line therapy or greater) in fourth quarter of 2019
  • 16 Oct 2019 4SC and Netherlands Cancer Institute collaborate for the phase Ib DONIMI trial for Melanoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top